The TAILOR-PCI Trial evaluates the outcomes between genotype-guided P2Y12 inhibitor selection versus conventional prescribing on ischemic outcomes. Listen to Geoff Wall and guest, Jake Galdo, discuss the role of pharmacogenomics in patient care.
Additional Resource/Reference:
https://jamanetwork.com/journals/jama/article-abstract/2769725
This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
